% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Blmeke:909074,
author = {Blömeke, Lara and Pils, Marlene and Kraemer-Schulien,
Victoria and Dybala, Alexandra and Schaffrath, Anja and
Kulawik, Andreas and Rehn, Fabian and Cousin, Anneliese and
Nischwitz, Volker and Willbold, Johannes and Zack, Rebecca
and Tropea, Thomas F. and Bujnicki, Tuyen and Tamgüney,
Gültekin and Weintraub, Daniel and Irwin, David and
Grossman, Murray and Wolk, David A. and Trojanowski, John Q.
and Bannach, Oliver and Chen-Plotkin, Alice and Willbold,
Dieter},
title = {{Q}uantitative detection of α-{S}ynuclein and {T}au
oligomers and other aggregates by digital single particle
counting},
journal = {npj Parkinson's Disease},
volume = {8},
number = {1},
issn = {2373-8057},
address = {London [u.a.]},
publisher = {Nature Publ. Group},
reportid = {FZJ-2022-02992},
pages = {68},
year = {2022},
abstract = {The pathological hallmark of neurodegenerative diseases is
the formation of toxic oligomers by proteins such as
alpha-synuclein (aSyn) or microtubule-associated protein tau
(Tau). Consequently, such oligomers are promising biomarker
candidates for diagnostics as well as drug development.
However, measuring oligomers and other aggregates in human
biofluids is still challenging as extreme sensitivity and
specificity are required. We previously developed
surface-based fluorescence intensity distribution analysis
(sFIDA) featuring single-particle sensitivity and absolute
specificity for aggregates. In this work, we measured aSyn
and Tau aggregate concentrations of 237 cerebrospinal fluid
(CSF) samples from five cohorts: Parkinson's disease (PD),
dementia with Lewy bodies (DLB), Alzheimer's disease (AD),
progressive supranuclear palsy (PSP), and a
neurologically-normal control group. aSyn aggregate
concentration discriminates PD and DLB patients from normal
controls (sensitivity $73\%,$ specificity $65\%,$ area under
the receiver operating curve (AUC) 0.68). Tau aggregates
were significantly elevated in PSP patients compared to all
other groups (sensitivity $87\%,$ specificity $70\%,$ AUC
0.76). Further, we found a tight correlation between aSyn
and Tau aggregate titers among all patient cohorts (Pearson
coefficient of correlation r = 0.81). Our results
demonstrate that aSyn and Tau aggregate concentrations
measured by sFIDA differentiate neurodegenerative disease
diagnostic groups. Moreover, sFIDA-based Tau aggregate
measurements might be particularly useful in distinguishing
PSP from other parkinsonisms. Finally, our findings suggest
that sFIDA can improve pre-clinical and clinical studies by
identifying those individuals that will most likely respond
to compounds designed to eliminate specific oligomers or to
prevent their formation.},
cin = {IBI-7},
ddc = {610},
cid = {I:(DE-Juel1)IBI-7-20200312},
pnm = {5244 - Information Processing in Neuronal Networks
(POF4-524) / 520 - Natural, Artificial and Cognitive
Information Processing (POF4-500)},
pid = {G:(DE-HGF)POF4-5244 / G:(DE-HGF)POF4-520},
typ = {PUB:(DE-HGF)16},
pubmed = {35655068},
UT = {WOS:000805184000001},
doi = {10.1038/s41531-022-00330-x},
url = {https://juser.fz-juelich.de/record/909074},
}